Supplementary Tables – Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib
dataset
posted on 2022-07-29, 08:22 authored by Figshare Future Science GroupFigshare Future Science Group, Dong-Hoon Lim, Andrea Casadei-Gardini, Myung Ah Lee, Sara Lonardi, Jin Won Kim, Gianluca Masi, Hong Jae Chon, Margherita Rimini, Ilhwan Kim, Jaekyung Cheon, Jun-Eul Hwang, Jung Hun Kang, Ho Yeong Lim, Changhoon Yoo<p> </p>
<p><strong>Supplementary Table S1</strong>. Baseline patient characteristics according to nationality</p>
<p> </p>
<p><strong>Supplementary Table S2</strong>. Baseline patient characteristics according to AFP response</p>
<p><br></p>
<p><strong>Supplementary Table S3. </strong>Univariate and multivariate analysis for PFS including baseline AFP </p>
<p><br></p>
<p><strong>Supplementary Table S4. </strong>Univariate and multivariate analysis for PFS including AFP response</p>
<p> </p>
<p><strong>Supplementary Table S5. </strong>Best overall tumor response by baseline AFP and AFP response</p>
History
Related Materials
- 1.
